S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:GRTX

Galera Therapeutics News Headlines

$1.27
0.00 (0.00%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.21
$1.30
50-Day Range
$1.27
$8.40
52-Week Range
$1.21
$12.99
Volume
835,600 shs
Average Volume
1.02 million shs
Market Capitalization
$33.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.12

Media Mentions By Week



Galera Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

GRTX
News Sentiment

0.55

0.36

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

GRTX Articles
This Week

1

0

GRTX Articles
Average Week

Get Galera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.

Galera Therapeutics (NASDAQ:GRTX) News Headlines Today

SourceHeadline
MarketBeat logoShort Interest in Galera Therapeutics, Inc. (NASDAQ:GRTX) Drops By 57.6%
americanbankingnews.com - November 29 at 1:10 PM
MarketBeat logoShort Interest in Galera Therapeutics, Inc. (NASDAQ:GRTX) Expands By 814.0%
americanbankingnews.com - November 15 at 1:24 PM
finance.yahoo.com logoGalera to Present at Two Upcoming Investor Conferences in November
finance.yahoo.com - November 15 at 7:46 AM
MarketBeat logoGalera Therapeutics, Inc. (NASDAQ:GRTX) Receives Consensus Recommendation of "Hold" from Analysts
americanbankingnews.com - November 15 at 5:42 AM
MarketBeat logoGalera Therapeutics (NASDAQ:GRTX) Issues Quarterly Earnings Results
americanbankingnews.com - November 12 at 7:54 PM
finance.yahoo.com logoGalera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
finance.yahoo.com - November 10 at 9:21 AM
finance.yahoo.com logoGalera Therapeutics, Inc. (GRTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
finance.yahoo.com - November 2 at 10:32 AM
finanznachrichten.de logoPre-market Movers: IFRX, CWBR, FUTU, MRAI, GRTX.
finanznachrichten.de - October 28 at 10:06 AM
finance.yahoo.com logoAll You Need to Know About Galera Therapeutics, Inc. (GRTX) Rating Upgrade to Buy
finance.yahoo.com - October 21 at 2:21 PM
bizjournals.com logoGalera's stock plunges 73% on disappointing test results for lead cancer drug candidate
bizjournals.com - October 19 at 2:35 PM
marketwatch.com logoGalera Therapeutics Shares Plunge After Study Failure >GRTX
marketwatch.com - October 19 at 2:35 PM
nasdaq.com logoGalera : Late-stage Trial Of Avasopasem On Severe Oral Mucositis Fails To Meet Main Goal; Stock Down
nasdaq.com - October 19 at 9:21 AM
finance.yahoo.com logoGalera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis
finance.yahoo.com - October 19 at 9:21 AM
finance.yahoo.com logoWhat Type Of Shareholders Make Up Galera Therapeutics, Inc.'s (NASDAQ:GRTX) Share Registry?
finance.yahoo.com - October 15 at 9:20 AM
finance.yahoo.com logoGalera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer
finance.yahoo.com - October 12 at 8:24 AM
finance.yahoo.com logoGalera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer
finance.yahoo.com - September 14 at 9:03 AM
finance.yahoo.com logoGalera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters
finance.yahoo.com - September 8 at 12:41 PM
finance.yahoo.com logoGalera to Present at Three Upcoming Investor Conferences in September
finance.yahoo.com - September 7 at 9:37 AM
finance.yahoo.com logoIs Galera Therapeutics (NASDAQ:GRTX) In A Good Position To Invest In Growth?
finance.yahoo.com - August 16 at 9:17 AM
finance.yahoo.com logoGalera Reports Second Quarter 2021 Financial Results and Recent Accomplishments
finance.yahoo.com - August 10 at 8:29 AM
finance.yahoo.com logoGalera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis
finance.yahoo.com - June 28 at 8:02 AM
finance.yahoo.com logoShould You Take Comfort From Insider Transactions At Galera Therapeutics, Inc. (NASDAQ:GRTX)?
finance.yahoo.com - June 3 at 1:08 PM
finance.yahoo.com logoGalera to Present at the Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 26 at 8:54 AM
finance.yahoo.com logoGalera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer
finance.yahoo.com - May 17 at 9:43 AM
finance.yahoo.com logoScience Translational Medicine Article Shows Galera’s Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors
finance.yahoo.com - May 12 at 7:00 PM
finance.yahoo.com logoGalera Reports First Quarter 2021 Financial Results and Recent Accomplishments
finance.yahoo.com - May 11 at 9:45 AM
finance.yahoo.com logoGalera to Participate in the BofA Securities 2021 Virtual Healthcare Conference
finance.yahoo.com - May 5 at 7:26 AM
bizjournals.com logoSt. Louis-born Galera's stock soars after release of positive study data for its experimental cancer therapy
bizjournals.com - April 30 at 3:48 PM
msn.com logoWhy Galera Therapeutics Stock is Trading Higher Today
msn.com - April 29 at 6:46 PM
markets.businessinsider.com logoMid-Day Market Update: Nasdaq Turns Lower; Galera Therapeutics Shares Surge
markets.businessinsider.com - April 29 at 1:45 PM
bizjournals.com logoGalera's stock soars after release of positive study data for its experimental cancer therapy
bizjournals.com - April 29 at 1:45 PM
finance.yahoo.com logoGalera Therapeutics Stock Surges After Its Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study
finance.yahoo.com - April 29 at 1:45 PM
finance.yahoo.com logoGalera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer
finance.yahoo.com - April 28 at 7:36 PM
finance.yahoo.com logoGalera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments
finance.yahoo.com - March 11 at 7:25 AM
finance.yahoo.com logoGalera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
finance.yahoo.com - March 10 at 8:15 AM
finance.yahoo.com logoWe Think Galera Therapeutics (NASDAQ:GRTX) Needs To Drive Business Growth Carefully
finance.yahoo.com - February 19 at 11:40 AM
finance.yahoo.com logoIs GRTX A Good Stock To Buy Now?
finance.yahoo.com - December 7 at 8:45 PM
finance.yahoo.com logoGalera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
finance.yahoo.com - November 10 at 10:09 AM
finance.yahoo.com logoGalera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
finance.yahoo.com - November 3 at 12:54 PM
seekingalpha.com logoAC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - October 30 at 7:36 AM
seekingalpha.com logoGalera down 6% on disappointing data on lead drug in pancreatic cancer
seekingalpha.com - October 27 at 11:45 PM
finance.yahoo.com logoGalera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer
finance.yahoo.com - October 27 at 6:45 PM
seekingalpha.com logoLianluo Smart, Galera Therapeutics leads healthcare gainers; BioSig Technologies, Aileron Therapeutics among major losers
seekingalpha.com - October 26 at 11:33 AM
finance.yahoo.com logoGalera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer
finance.yahoo.com - October 23 at 8:46 PM
barrons.com logoGalera Therapeutics Inc.
barrons.com - October 23 at 3:42 PM
seekingalpha.com logoDosing underway for Galera Therapeutics' GC4711 in early-stage lung cancer study
seekingalpha.com - October 22 at 2:17 PM
finance.yahoo.com logoGalera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer
finance.yahoo.com - October 22 at 9:13 AM
finance.yahoo.com logoHow Many Galera Therapeutics, Inc. (NASDAQ:GRTX) Shares Do Institutions Own?
finance.yahoo.com - October 20 at 11:09 AM
benzinga.com logoGalera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer
benzinga.com - September 22 at 8:32 AM
seekingalpha.com logoDosing is underway for Galera's lead asset in mid-stage COVID-19 study
seekingalpha.com - September 16 at 1:29 PM
Get Galera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.